Remove Allergies Remove In-Vitro Remove Nurses Remove Protein
article thumbnail

Pfizer Responds to Research Claims

Pfizer

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. and global regulatory requirements for our oral treatment, PAXLOVIDâ„¢, Pfizer undertakes in vitro work (e.g., It is important to note that these studies are required by U.S.

Research 112
article thumbnail

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. Read on to see. COVID-19-Related. It also has robust antimicrobial properties.

Trials 52
article thumbnail

COVID-19 Pandemic Coverage

XTalks

These companies include Moderna, a US biotech company which has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID), Oxford University who has partnered with AstraZeneca, and Johnson & Johnson, Merck and Pfizer. The price of that prize is incalculable. Moderna’s COVID-19 Vaccine.